

Major or Mild Neurocognitive Disorder Due to Vascular Disease

DSM-5-TR 290.40 MAJOR, 331.83 MILD | ICD-10-CM F01.5X, G31.84

Cognitive decline caused by cerebrovascular disease, classically stepwise, with executive dysfunction and slowed processing leading the picture.

SHARE OF DEMENTIA

~15-20% of dementia cases

TYPICAL ONSET

After 65; earlier post-stroke

SEX RATIO

Slight male predominance

COURSE

Stepwise; ~5 yr median survival

CLINICAL PICTURE

- Processing speed, complex attention, and executive function fall before memory, so patients appear slowed and disorganized rather than forgetful.
- Decline is classically stepwise after clinical strokes, but small vessel disease produces a gradual course that mimics Alzheimer's on history alone.
- Focal neurological findings are common: gait disturbance, urinary urgency, brisk reflexes, pseudobulbar affect, and early falls.
- Memory failure is retrieval-based and improves with cueing and recognition, unlike the rapid forgetting and failed encoding of Alzheimer's disease.
- Apathy, emotional lability, and post-stroke depression are prominent and often burden families more than the cognitive deficits themselves.
- Insight is relatively preserved early, so patients report their own decline more often than families do at first presentation.

NEUROBIOLOGY & PHYSIOLOGY

- Mechanisms span large-vessel infarcts, strategic single infarcts in thalamus or angular gyrus, lacunes, hemorrhage, and diffuse white matter ischemia.
- Subcortical small vessel disease disconnects frontal-subcortical circuits, which explains the executive and processing-speed signature of the syndrome.
- MRI shows white matter hyperintensities, lacunes, microbleeds, and enlarged perivascular spaces, graded with the Fazekas scale and STRIVE criteria.
- Hypertension, diabetes, atrial fibrillation, smoking, dyslipidemia, and obstructive sleep apnea are the dominant modifiable risk factors.
- CADASIL, caused by NOTCH3 mutations, produces early-onset subcortical disease with migraine with aura and merits testing before age 60.
- Mixed Alzheimer's and vascular pathology is the most common substrate found at autopsy in dementia beginning after age 80.

PSYCHOLOGICAL MECHANISMS

- Frontal-subcortical disconnection produces apathy that families read as laziness or depression, a distinction that changes the entire management plan.
- Insight preserved early in the course drives real demoralization, and post-stroke depression affects roughly one-third of stroke survivors.
- Pseudobulbar affect, with laughing or crying detached from felt emotion, distresses families, is commonly misread as lability, and is treatable.
- Slowed processing means patients answer correctly when given time, so rushed interviews and hurried caregiving manufacture apparent impairment.
- Behavioral activation and structured routine counter apathy far more reliably than encouragement or insight-oriented approaches.

DIAGNOSTIC CRITERIA AT A GLANCE

- Criteria for major or mild neurocognitive disorder are met, with decline documented by informant report plus objective cognitive testing.
- Clinical features suggest a vascular etiology: onset tied to a cerebrovascular event, or prominent decline in complex attention and frontal executive function.
- Evidence of cerebrovascular disease from history, physical examination, or neuroimaging is sufficient to account for the observed deficits.
- Probable vascular etiology requires neuroimaging support, a clear temporal link to stroke, or genetic evidence; otherwise the etiology is called possible.
- Symptoms are not better explained by another brain disease or systemic disorder; specify major or mild, with or without behavioral disturbance.

DIFFERENTIAL & COMORBIDITY

- Alzheimer's disease shows insidious amnesic onset with little benefit from cueing, while vascular disease shows executive slowing with focal signs.
- Lewy body disease brings fluctuating attention, visual hallucinations, parkinsonism, and REM sleep behavior disorder, with gait overlap adding confusion.
- Normal pressure hydrocephalus presents with gait apraxia, urinary incontinence, and cognitive slowing, and is potentially reversible with shunting.
- Depression, delirium, obstructive sleep apnea, and medication effects mimic or amplify vascular cognitive impairment and should be treated first.
- Stroke, cardiac disease, diabetes, and depression coexist as the rule, so care is inherently multidisciplinary and medically driven.

Treatment EVIDENCE-BASED MANAGEMENT

PHARMACOLOGIC

- Secondary stroke prevention is the core treatment: antihypertensives, **statins**, antiplatelet therapy, and anticoagulation for atrial fibrillation.
- Target blood pressure below 130/80 mm Hg where tolerated, since intensive control reduced incident cognitive impairment in randomized trials.
- Cholinesterase inhibitors and memantine offer minimal benefit in pure vascular disease, though they are reasonable when Alzheimer's pathology coexists.
- Treat post-stroke depression with an **SSRI** such as **sertraline** or **escitalopram**, weighing bleeding risk alongside antithrombotic therapy.
- Dextromethorphan-quinidine** is approved for pseudobulbar affect and rapidly reduces involuntary episodes of crying and laughing.

PSYCHOTHERAPY

- Cognitive rehabilitation** aimed at attention, planning, and error monitoring fits the executive profile far better than memory drills.
- Behavioral activation** and problem-solving therapy treat post-stroke depression and apathy, with good evidence in rehabilitation settings.
- Caregiver psychoeducation** reframes apathy as a symptom of brain injury rather than a choice, which reduces conflict and caregiver strain.
- CBT** adapted for slowed processing, using shorter sessions and written summaries, treats comorbid anxiety and depression effectively.
- Goal-oriented rehabilitation with occupational and speech therapy after stroke yields real functional gains over the following months.

ADJUNCT & SUPPORTIVE

- Cardiovascular risk management is dementia treatment here: blood pressure, glucose, lipids, smoking cessation, and atrial fibrillation control.
- Aerobic exercise improves executive function and gait, and structured physical therapy reduces the fall risk that drives hospitalization.
- Treat obstructive sleep apnea with CPAP, since untreated apnea worsens vascular risk and cognitive performance simultaneously.
- Assess with the **MoCA**, which detects the executive deficits the MMSE misses, adding clock draw and trail making for frontal function.
- Address driving safety, falls, home modification, and advance care planning early, given the stepwise and unpredictable trajectory.

- ☆ **CLINICAL PEARLS**
- Executive slowing with focal neurological signs, not amnesia, is the vascular signature.
 - Cueing rescues recall in vascular disease; in Alzheimer's disease it does not.
 - Treating blood pressure is the most effective drug therapy available here.

References

American Psychiatric Association. (2022). *Diagnostic and statistical manual of mental disorders* (5th ed., text rev.).

<https://doi.org/10.1176/appi.books.9780890425787>

Boland, R., Verduin, M. L., & Ruiz, P. (2021). *Kaplan & Sadock's synopsis of psychiatry* (12th ed.). Wolters Kluwer.

Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., Costafreda, S. G.,

Dias, A., Fox, N., Gitlin, L. N., Howard, R., Kales, H. C., Kivimaki, M., Larson, E. B., Ogunniyi, A., ... Mukadam, N. (2020). Dementia

prevention, intervention, and care: 2020 report of the Lancet Commission. *The Lancet*, 396(10248), 413-446. [https://doi.org/10.1016/S0140-](https://doi.org/10.1016/S0140-6736(20)30367-6)

6736(20)30367-6

National Institute for Health and Care Excellence. (2018). *Dementia: Assessment, management and support for people living with dementia and*

their carers (NICE Guideline No. NG97). <https://www.nice.org.uk/guidance/ng97>

O'Brien, J. T., & Thomas, A. (2015). Vascular dementia. *The Lancet*, 386(10004), 1698-1706.

Stahl, S. M. (2021). *Stahl's essential psychopharmacology: Neuroscientific basis and practical applications* (5th ed.). Cambridge University Press.

World Health Organization. (2019). *International classification of diseases for mortality and morbidity statistics* (11th rev.).

<https://icd.who.int/browse11>

NOTE

References are formatted in APA 7th edition style with hanging indents. Diagnostic terminology, criteria structure, and coding follow the *Diagnostic and Statistical Manual of Mental Disorders* (5th ed., text rev.; APA, 2022); criteria are paraphrased for instructional use and are not reproduced verbatim. Verify all citations against the original sources before use in academic work, and confirm medication dosing against current prescribing information.